Evaluation of temozolomide in patients with myelodysplastic syndrome

Leukemia & Lymphoma
Karen SeiterTauseef Ahmed

Abstract

In our previous phase I study of temozolomide in patients with acute leukemia, temozolomide was well tolerated and demonstrated significant anti-leukemic activity. The maximum tolerated dose was 200 mg/m2/d for 7 days, repeated approximately every 5-6 weeks. In the current study, we evaluated the same dose of temozolomide in patients with myelodysplastic syndrome. Fourteen patients received 19 courses of temozolomide. The median age was 71 years. In this study, treatment was poorly tolerated with patients requiring admission in 9 of 19 courses. Toxicity included worsening cytopenias, neutropenic fever, and exacerbation of cardiac disease, the latter due to worsening anemia. An unusual finding was the development of leukocytoclastic vasculitis in 4 patients. There were no formal responses to therapy. The current schedule of temozolomide is not efficacious in patients with myelodysplastic syndrome.

References

Sep 5, 1995·Biochemical and Biophysical Research Communications·K InokuchiT Shimada
Jan 1, 1995·Leukemia & Lymphoma·C AulW Schneider
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S M O'ReillyP Lewis
Dec 24, 1997·British Journal of Haematology·J J MolldremA J Barrett
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W K YungV A Levin
Apr 18, 2000·Mutation Research·A E Pegg
Aug 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karen SeiterTauseef Ahmed
Dec 17, 2002·Leukemia & Lymphoma·Lenka Krsková-HonzátkováZuzana Sieglová

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Karen SeiterTauseef Ahmed
Current Neurology and Neuroscience Reports
Roger StuppMonika E Hegi
© 2021 Meta ULC. All rights reserved